Jean Campbell reflects on why the patient voice needs to be not just heard but acknowledged.
Read More
When pharma treats patients as partners, it’s much easier to reach our shared goal of better health. In our final J.P. Morgan blog post, Chris Smith weighs in.
When it comes to orphan drugs, particularly gene therapy, the pricing problem stems from visibility rather than dollars.
At this year’s J.P. Morgan Healthcare Conference, David Lapidus spoke with biopharma investors about our nation’s new leader. Here’s what happened.
Doug Paul provides his perspective on pricing and reimbursement models for gene therapies.
Doug Paul talks about the challenges that orphan drugs face after regulatory approval.
RARE COLLECTIVE® is a trademark of Rare Collective, LLC. 